Ara D Metjian MD
Clotting Disorder, Hemophilia & Bleeding Disorder
Assistant Professor of Medicine, Duke University School of Medicine
Join to View Full Profile
1665 Aurora CtAurora, CO 80045
Phone+1 720-848-0000
Fax+1 720-848-1786
Dr. Metjian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ara Metjian is a Benign Hematologist. He completed his residency in Internal Medicine at the University of North Carolina Hospitals, followed by a fellowship in Hematology and Medical Oncology at the University of Pennsylvania Health System. Dr. Metjian graduated from Drexel University College of Medicine in 2001. His research has been published in recognized journals, including multiple articles in Blood and Blood Advances. He has received the CMS Meaningful Use Stage 1 Certification from EpicCare Ambulatory EMR by Epic Systems Corporation.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2005 - 2007
University of North Carolina HospitalsResidency, Internal Medicine, 2001 - 2004
Drexel University College of MedicineClass of 2001
Certifications & Licensure
CO State Medical License 2020 - 2027
NC State Medical License 2001 - 2025
PA State Medical License 2005 - 2010
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Publications & Presentations
PubMed
- Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era.Ayotola Fatola, Michael D Evans, Jenna Brown, Elizabeth Davis, Andrew Johnson
Blood Advances. 2025-01-28 - A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura.Mouhamed Yazan Abou-Ismail, Chong Zhang, Angela P Presson, Shruti Chaturvedi, Ana G Antun
Research and Practice in Thrombosis and Haemostasis. 2024-03-01 - 2 citationsA descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry.Mouhamed Yazan Abou-Ismail, Chong Zhang, Angela P Presson, Shruti Chaturvedi, Ana G Antun
Blood Advances. 2024-02-13
Abstracts/Posters
- Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression RegimenAra Metjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease SeverityAra Metjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian PopulationsAra Metjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
